1.         Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        MEA Non-Alcoholic Steatohepatitis Market – By Product

1.3.2        MEA Non-Alcoholic Steatohepatitis Market – By Application

1.3.3        MEA Non-Alcoholic Steatohepatitis Market – By Sales Channel

1.3.4        MEA Non-Alcoholic Steatohepatitis Market – By Country

2.           Key Takeaways

3.        Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           MEA Non-Alcoholic Steatohepatitis Market – Market Landscape

4.1         Overview

4.2         PEST Analysis

4.2.1        Middle East And Africa PEST Analysis

4.3         Experts Opinion

5.           MEA Non-alcoholic steatohepatitis (NASH) Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Rising Prevalence of NASH

5.1.2        Increasing Initiatives for the Awareness of NASH

5.2         Market Restraints

5.2.1        Lack of Established Guidelines in the Diagnosis and Management of NASH

5.2.2        Withdrawal of Drugs from Seeking Marketing Authorization for NASH

5.3         Market Opportunities

5.3.1        Growing Opportunities in Developing Nations

5.3.2        High Competition among Market Players to Manufacture the First Marketed NASH Drug Creates Global Sales Opportunity

5.4         Future Trends

5.4.1        Growing Clinical Trials Involving Combination Studies of Drugs

5.5         Impact Analysis

6.           Non-alcoholic steatohepatitis (NASH) Market– MEA Analysis

6.1         MEA Non-Alcoholic Steatohepatitis Market Revenue Forecast and Analysis

7.           MEA Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts To 2028– by Product

7.1         Overview

7.2         Product Market Revenue and Forecast Analysis (US$ Mn)

7.3         Vitamin E and Pioglitazone

7.3.1        Overview

7.3.2        Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)

7.4         Ocaliva

7.4.1        Overview

7.4.2        Ocaliva Revenue and Forecast to 2028 (US$ Mn)

7.5         Elafibranor

7.5.1        Overview

7.5.2        Elafibranor Revenue and Forecast to 2028 (US$ Mn)

7.6         Selonsertib & Cenicriviroc

7.6.1        Overview

7.6.2        Selonsertib Revenue and Forecast to 2028 (US$ Mn)

7.7         Others

7.7.1        Overview

7.7.2        Others Revenue and Forecast to 2028 (US$ Mn)

8.           MEA Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Application

8.1         Overview

8.2         Application Market Revenue and Forecast Analysis (US$ Mn)

8.3         Treatment

8.3.1        Overview

8.3.2        Treatment Market Revenue and Forecast to 2028 (US$ Mn)

8.4         Diagnosis

8.4.1        Overview

8.4.2        Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)

9.           MEA Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Sales Channel

9.1         Overview

9.2         Sales Channel Market Revenue and Forecast Analysis (US$ Mn)

9.3         Hospital Pharmacy

9.3.1        Overview

9.3.2        Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

9.4         Retail Pharmacy

9.4.1        Overview

9.4.2        Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

9.5         Online Provider

9.5.1        Overview

9.5.2        Online Provider Market Revenue and Forecast to 2028 (US$ Mn)

10.        MEA Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts to 2028 – Country Analysis

10.1      Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market

10.1.1     Overview

10.1.2     Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Country (%)

10.1.2.1       UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.1.2.1.1       UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.1.2.1.2       UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

10.1.2.1.3       UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast To 2028, By Application (US$ Million)

10.1.2.1.4       UAE: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)

10.1.2.2       Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.1.2.2.1       Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.1.2.2.2       Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

10.1.2.2.3       Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast To 2028, By Application (US$ Million)

10.1.2.2.4       Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)

10.1.2.3       South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.1.2.3.1       South Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.1.2.3.2       South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

10.1.2.3.3       South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast To 2028, By Application (US$ Million)

10.1.2.3.4       South Africa: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.1.2.4       Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.1.2.4.1       Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

10.1.2.4.2       Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

10.1.2.4.3       Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast To 2028, By Application (US$ Million)

10.1.2.4.4       Rest of Middle East & Africa: D Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

11.        Industry Landscape

11.1      Overview

11.2      Organic Developments

11.2.1     Overview

11.3      Inorganic Developments

11.3.1     Overview

12.        Company Profiles

12.1      Cadila Pharmaceuticals Ltd.

12.1.1     Key Facts

12.1.2     Business Description

12.1.3     Products and Services

12.1.4     Financial Overview

12.1.5     SWOT Analysis

12.1.6     Key Developments

12.2      Intercept Pharmaceuticals, Inc

12.2.1     Key Facts

12.2.2     Business Description

12.2.3     Products and Services

12.2.4     Financial Overview

12.2.5     SWOT Analysis

12.2.6     Key Developments

12.3      Novartis AG

12.3.1     Key Facts

12.3.2     Business Description

12.3.3     Products and Services

12.3.4     Financial Overview

12.3.5     SWOT Analysis

12.3.6     Key Developments

12.4      Galmed Pharmaceuticals.

12.4.1     Key Facts

12.4.2     Business Description

12.4.3     Products and Services

12.4.4     Financial Overview

12.4.5     SWOT Analysis

12.4.6     Key Developments

12.5      GENFIT.

12.5.1     Key Facts

12.5.2     Business Description

12.5.3     Products and Services

12.5.4     Financial Overview

12.5.5     SWOT Analysis

12.5.6     Key Developments

12.6      Siemens Healthineers AG

12.6.1     Key Facts

12.6.2     Business Description

12.6.3     Products and Services

12.6.4     Financial Overview

12.6.5     SWOT Analysis

12.6.6     Key Developments

12.7      Laboratory Corporation of America Holdings

12.7.1     Key Facts

12.7.2     Business Description

12.7.3     Products and Services

12.7.4     Financial Overview

12.7.5     SWOT Analysis

12.7.6     Key Developments

13.        Appendix

13.1      About The Insight Partners

13.2      Glossary of Terms

LIST OF TABLES

Table 1.             UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

Table 2.             UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Application (US$ Million)

Table 3.             UAE: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)

Table 4.             Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

Table 5.             Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Application (US$ Million)

Table 6.             Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)

Table 7.             South Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

Table 8.             South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Application (US$ Million)

Table 9.             South Africa: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 10.          Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)

Table 11.          Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Application (US$ Million)

Table 12.          Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 13.          Organic Developments Done By Companies

Table 14.          Inorganic Developments Done By Companies

Table 15.          Glossary of Terms

LIST OF FIGURES

Figure 1.           MEA Non-Alcoholic Steatohepatitis Market Segmentation

Figure 2.           MEA Non-Alcoholic Steatohepatitis Market, By Country

Figure 3.           MEA Non-Alcoholic Steatohepatitis Market Overview

Figure 4.           MEA Non-Alcoholic Steatohepatitis Market, By Application

Figure 5.           MEA Non-Alcoholic Steatohepatitis Market, By Country

Figure 6.           Middle East And Africa: PEST Analysis

Figure 7.           MEA Experts Opinion

Figure 8.           MEA Non-Alcoholic Steatohepatitis (NASH) Market Impact Analysis of Drivers and Restraints

Figure 9.           MEA Non-Alcoholic Steatohepatitis Market– Revenue Forecast and Analysis

Figure 10.        MEA Product Market Analysis and Forecast 2021 and 2028 (%)

Figure 11.        MEA Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)

Figure 12.        MEA Ocaliva Revenue and Forecast to 2028 (US$ Mn)

Figure 13.        MEA Elafibranor Revenue and Forecast to 2028 (US$ Mn)

Figure 14.        MEA Selonsertib Revenue and Forecast to 2028 (US$ Mn)

Figure 15.        MEA Others Revenue and Forecast to 2028 (US$ Mn)

Figure 16.        MEA Application Market Analysis and Forecast 2021 and 2028 (%)

Figure 17.        MEA Treatment Market Revenue and Forecast to 2028 (US$ Mn)

Figure 18.        MEA Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)

Figure 19.        MEA Sales Channel Market Analysis and Forecast 2021 and 2028 (%)

Figure 20.        MEA Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

Figure 21.        MEA Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

Figure 22.        MEA Online Provider Market Revenue and Forecast to 2028 (US$ Mn)

Figure 23.        Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue Overview, by Country, 2021 (US$ Million)

Figure 24.        Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Country (%)

Figure 25.        UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

Figure 26.        Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

Figure 27.        South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)

Figure 28.        Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)